(9-phenylcarbazol-2-yl)boronic acid | CAS:1001911-63-2

We serve (9-phenylcarbazol-2-yl)boronic acid CAS:1001911-63-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
(9-phenylcarbazol-2-yl)boronic acid

Chemical Name:(9-phenylcarbazol-2-yl)boronic acid
CAS.NO:1001911-63-2
Synonyms:(9-Phenyl-9H-carbazol-2-yl)boronic acid
N-phenylcarbazole-2-boronic acid
Molecular Formula:C18H14BNO2
Molecular Weight:287.12000
 
Physical and Chemical Properties:
Boiling point:112ºC
 
Specification:
Appearance:Off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like (9-phenylcarbazol-2-yl)boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-phenylcarbazole-2-boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(9-phenylcarbazol-2-yl)boronic acid Use and application,(9-phenylcarbazol-2-yl)boronic acid technical grade,usp/ep/jp grade.


Related News: After this long manufacturing process, it is purified until it reaches a very high degree of purity and finally becomes an API.(R)-3-Aminobutan-1-ol manufacturer Refers to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs or innovative drugs). It mainly meets the needs of international original research drug companies and emerging biopharmaceutical companies for innovative drugs at various stages of clinical research, registration approval and commercialization of drugs. Contains advanced intermediates used in the manufacture of this drug substance that need to be regulated by regulatory authorities.4-bromoanisole supplier ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.4-[(4-Methyl-1-piperazinyl)methyl]benzoic acid vendor ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.Who is at risk of infection? People of all ages can be infected with the virus, but older people and those with pre-existing medical conditions are especially vulnerable to severe complications.